Automated Deauville Score computation from baseline [¹⁸F]FDG PET/CT predicts progression-free survival in multiple myeloma: a radiogenomic framework
PURPOSE: F]FDG PET/CT in multiple myeloma (MM) relies on visual interpretation, limiting reproducibility. This study aimed to develop an automated pipeline for standardised DS computation, evaluate the prognostic value of DS at five anatomical sites, and predict progression-free survival (PFS) by integrating DS with copy number alterations (CNA) and clinical variables. METHODS: A retrospective cohort of 165 newly diagnosed MM patients with baseline FDG PET/CT, CNA profiling, and blood tests was analysed. An automated pipeline computed DS fully automatically for vertebral bone marrow (BM) and long bones (LB), and semi-automatically for focal (FL), paramedullary (PM), and extramedullary (EM) lesions. DS were subdivided into absent (1), low (2-3), and high (4-5) groups and compared via log-rank test. A penalised Cox model with 12 covariates (five DS, three CNAs, haemoglobin, platelet count, age, sex) was evaluated via nested cross-validation for PFS prediction. For inference on individual prognostic contributions, an unpenalised multivariable Cox model was fitted on the full cohort. RESULTS: In univariate analyses, high LB, PM and EM DS were significantly associated with shorter PFS. The penalised Cox model achieved a C-index of 0.710 [95% CI: 0.689-0.732] in predicting the risk of progression. In the multivariable analysis, age, haemoglobin, BM DS, PM DS and amp(1q) were identified as independent prognostic factors. CONCLUSION: Automated DS computation from baseline FDG PET/CT is feasible and, combined with genomic and clinical data, enables a reproducible multimodal approach to prognostic stratification in MM. The pipeline for DS computation is publicly available as an open-source tool (autoDS-PET) at https://github.com/Sara-Peluso/autoDS-PET .
Authors
- Valentino Dragonetti
- Gastone Castellani (ORCID: https://orcid.org/0000-0003-4892-925X)
- Ettore Rocchi (ORCID: https://orcid.org/0000-0002-7612-2819)
- Carolina Terragna (ORCID: https://orcid.org/0000-0002-4948-4785)
- Stefano Polizzi (ORCID: https://orcid.org/0000-0002-5264-5156)
- Claudia Sala (ORCID: https://orcid.org/0000-0002-4889-1047)
- Daniele Dall’Olio (ORCID: https://orcid.org/0000-0003-0196-6870)
- Vincenza Solli (ORCID: https://orcid.org/0000-0002-4828-6955)
- Elena Zamagni (ORCID: https://orcid.org/0000-0003-1422-7305)
- Stefano Fanti (ORCID: https://orcid.org/0000-0003-1486-2624)
- Cristina Nanni (ORCID: https://orcid.org/0000-0003-2000-1599)
- Martina Tarozzi (ORCID: https://orcid.org/0000-0002-4240-0542)
- Sara Peluso (ORCID: https://orcid.org/0000-0003-1924-1093)
- Marco Talarico (ORCID: https://orcid.org/0009-0005-3408-0461)
- Lisa Pagnini (ORCID: https://orcid.org/0009-0009-8081-1252)
Institutions
- Istituto di Ematologia di Bologna (IT)
- Azienda USL di Bologna (IT)
- Istituto delle Scienze Neurologiche di Bologna (IT)
- European Institute of Oncology (IT)
- University of Bologna (IT)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2026-07-30
- DOI
- https://doi.org/10.1007/s00259-026-08103-x
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Associazione Italiana per la Ricerca sul Cancro
- Horizon 2020 Framework Programme
- HORIZON EUROPE Framework Programme